We are Sorry, This Page doesn't Exist
Biogen"s stock is up 5% after Lilly reports positive data from an Alzheimer"s study
Shares of Biogen Inc. gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen therapy under review by the Food and Drug A.....»»
CORRECTING AND REPLACING -- Arbor Realty Trust Schedules Fourth Quarter 2019 Earnings Conference Call
UNIONDALE, N.Y., Feb. 11, 2020 (GLOBE NEWSWIRE) -- In a release issued February 5, 2020, by Arbor Realty Trust, Inc. (NYSE:ABR), the time of their conference call to review fourth quarter .....»»
FDA Grants Priority Review Designation For Clovis Oncology"s Rubraca Label Expansion
Clovis Oncology Inc (NASDAQ: CLVS) shares are advancing strongly after the company clinched a regulatory milestone with respect to its oncology drug Rubraca. 0 read more.....»»
TMX Group Limited announces release date for Q4 2019 financial results and analyst conference call
TORONTO, Jan. 13, 2020 /CNW/ - TMX Group Limited will announce its financial results for the fourth quarter and year ended December 31, 2019 in the evening of Monday, February 10, 2020. An analyst conference call to review the results will be held.....»»
AstraZeneca Shares Trade Higher After FDA Grants Breast Cancer Drug Priority Review
AstraZeneca plc (NYSE: AZN) and partner DAIICHI SANKYO/S ADR (OTC: DSNKY) announced positive news Thursday on their HER-2 targeting antibody drug conjugate, or ADC. read more.....»»
Cerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder
Shares of Cerecor Inc. rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S. Food and Drug Administration has awarded it an expedited review process for a treatment for Manno.....»»
Nektar Therapeutics Tumbles To 2-Year Low On Q2 Revenue Miss, Manufacturing Issues With Cancer Drug
Nektar Therapeutics (NASDAQ: NKTR) shares were plummeting to a two-year low Friday following the release .....»»
Nektar Therapeutics Tumbles To 2-Year Low On Q2 Revenue Miss, Manufacturing Issues With Cancer Drug
Nektar Therapeutics (NASDAQ: NKTR) shares were plummeting to a two-year low Friday following the release of its quarterly results the prior afternoon, wiping away roughly $1.9 billion of its marke read more.....»»
Krystal Biotech shares up 27% after company"s skin drug receives expedited review designation from FDA
Shares of Krystal Biotech Inc. were up 27% in Monday intraday trade after the gene therapy company said it had receive.....»»
Drug stock soars 250% on pneumonia treatment review
Melinta Therapeutics shares nearly doubled early on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Baxdela (delafloxacin) for priority review......»»
Drug stock soars 250 percent on pneumonia treatment review
Melinta Therapeutics shares nearly doubled early on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Baxdela (delafloxacin) for priority review......»»
Drug stock soars 250 percent on pneumonia treatment review
Melinta Therapeutics shares nearly doubled early on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Baxdela (delafloxacin) for priority review......»»
Drug stock soars after FDA gives nod to pneumonia treatment
Melinta Therapeutics shares nearly doubled early on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Baxdela (delafloxacin) for priority review......»»
Eli Lilly misses estimates for top-selling diabetes drug Trulicity, shares slip
Eli Lilly and Co reported lower-than-expected sales for its top-selling diabetes drug Trulicity on Tuesday and said it expects further hits from price declines in the United States, sending its shares down 3 percent......»»
Zogenix shares down 23% after FDA refuses to review company’s marketing application for seizure drug
Shares of Zogenix, Inc. plunged 23% Tuesday after the company disclosed Monday evening that the Food and Drug Administration had refused to review the marketing application for a treatment of seizures associated with a rare form of childhood epilepsy......»»
Aldeyra"s Eye Inflammation Drug Aces Late-Stage Trial, Stock Rises 60%
Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares are advancing strongly Tuesday following the release of the results of a late-stage study of its drug candidate for allergic conjunctivitis. Latest R.....»»
FDA Delays Selinexor Approval By 3 Months — So Why Is Karyopharm Ripping Higher?
Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares, which suffered a setback in late February following the release of the FDA's briefing document and panel vote on its multiple myeloma treatment c Latest Ratings for KPTI.....»»
HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside
Aerpio Pharmaceuticals Inc (OTC: ARPO), an OTC-listed company specializing in drug development for ocular diseases, earned a bullish review Wednesday. The interest in the stock can only go higher, as the company seeks to up-list the shares.....»»
Alkermes Rallies as FDA Accepts NDA for Depression Drug
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depre.....»»
Alkermes"s stock soars after FDA accepts NDA review, 2 weeks after refusing
Shares of Alkermes PLC soared 21% in premarket trade Monday, after the biopharmaceutical company said the Food and Drug Administration accepted for review the company's new drug application (NDA) for.....»»